Euro zone banks see rising loan demand despite trade standoff, ECB survey shows
Bank lending, the primary source of finance for businesses, has been slowly recovering for the past year as the ECB has cut interest rates quickly, and firms remained relatively upbeat about their prospects despite a trade standoff with the United States.
"Loan demand was supported by declining interest rates, but dampened by global uncertainty and trade tensions," the ECB said based on a quarterly survey of 155 lenders.
The ECB is all but certain to keep interest rates unchanged on Thursday but will keep the door open to further easing later this year, and markets still expect one more rate cut before the bank is done lowering borrowing costs.
Credit standards - banks' internal guidelines or loan approval criteria - were unchanged for firms last quarter, despite earlier expectations for a modest tightening, and lenders see little change in the current quarter.
While perceived risks related to the economic outlook continued to contribute to a tightening of credit standards, banks reported no specific additional tightening related to geopolitical uncertainty and trade tensions, the ECB added.
Credit standards tightened in commercial real estate, manufacturing, wholesale and retail trade and construction, while they eased slightly across most services.
Demand for housing loans continued to increase substantially last quarter and banks see a further rapid increase in the third quarter, the ECB added.
Credit standards for mortgages tightened slightly but banks see a modest easing in the current quarter, the ECB added.
In consumer credit, there was a more pronounced tightening of standards last quarter and banks see further tightening ahead.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Auto Blog
an hour ago
- Auto Blog
Chevy Just Set An Insane EV Range Record—In A Big Truck
By signing up I agree to the Terms of Use and acknowledge that I have read the Privacy Policy . You may unsubscribe from email communication at anytime. Autoblog brings you car news; expert reviews and exciting pictures and video. Research and compare vehicles, too. View post: Official: The Cadillac XT5 Is Sticking Around With a Mild-Hybrid Update for 2027 This 1967 Jaguar XKE Series 4.2 is a stunning example of British motoring history, beautifully preserved, period-correct, and ready to be enjoyed or shown. View post: Amazon Is Selling a 'Powerful' Greenworks Chainsaw for 43% Off, and Shoppers Say It's 'Game Changer' View post: Wayfair Is Selling a 'Very Sturdy' $350 Sterilite Storage Cabinet for Only $115, and It 'Keeps Things Organized' No hardware or software changes were required to set a new record It's been a record-breaking month for Chevrolet. Already, the company set a new record for American cars at the Nürburgring with the Corvette ZR1 and ZR1X. Its latest record won't be as exciting for gearheads, as it involves the longest range on a full charge for an EV, but it's another stellar technical achievement. 300 miles is generally accepted as the psychological mark of a useful EV range, but Lucid far surpassed this by hitting 749 miles in the Air sedan last month—a record at the time. Chevy has now crushed that figure, and even more impressively, it pulled off the feat with a heavy, full-size pickup, not an aerodynamic sedan. Over 1,000 Miles On A Full Charge Source: GM The record-breaking achievement came behind the wheel of a 2026 Chevrolet Silverado EV Max Range Work Truck, which went 1,059.2 miles on a full charge, breaking Lucid's 749-mile record. This truck is rated by the EPA for a 493 mile range, so how was it able to more than double that figure? GM says the record attempt began with a casual conversation between GM engineers late last year. They started guessing what sort of range they could achieve if the pickup could be optimized for range and efficiency. Source: GM 'Getting this kind of range on a full charge doesn't happen by accident,' said Kurt Kelty, VP, battery, propulsion, and sustainability. 'It takes deep integration across battery chemistry, drive unit efficiency, software and vehicle engineering—and that's exactly what the team delivered. This achievement is a great example of how far our EV technology has come, and the kind of innovation we're building on every day at GM.' Autoblog Newsletter Autoblog brings you car news; expert reviews and exciting pictures and video. Research and compare vehicles, too. Sign up or sign in with Google Facebook Microsoft Apple By signing up I agree to the Terms of Use and acknowledge that I have read the Privacy Policy . You may unsubscribe from email communication at anytime. Real-World Test Sees Staggering Results Source: GM The GM team performed the record-breaking test on public roads in southeastern Michigan, close to GM's Milford Proving Ground. The team optimized every feasible aspect of the truck, but left the hardware and software as is. While it's technically possible for owners of the truck to put some of these optimizing measures in place, combining them all will be just about impossible in normal driving. These were the measures taken by the team: When conditions allowed, drivers averaged 20 to 25 mph, and hard braking was minimized No passengers were in the truck for most of the test Windshield wiper arms were set to the lowest possible position, reducing drag The highest acceptable tire pressure was used, resulting in lower rolling resistance The wheel alignment was optimized and the spare tire was removed The climate control wasn't used at all For smoother airflow, an accessory tonneau cover was added The test occurred in warmer summer conditions None of these measures are particularly groundbreaking, but the cumulative effect clearly made all the difference. The various engineers who drove the truck did so in one-hour shifts, allowing them to incorporate the project into their normal work schedules. Source: GM 'If we drove it downhill the whole time, sure, we'd get insane mileage,' said Jon Doremus, propulsion calibration engineering manager. 'But that's not what this was about. We wanted this to be real, on public roads.' The test suggests that by incorporating just a few of these measures, owners of this Chevy pickup should easily be able to squeeze over 500 miles of range from it, a commendable effort. The EPA rating of the Chevy is already better than all other rivals, including the Rivian R1T, Tesla Cybertruck, and Ford F-150 Lightning. About the Author Karl Furlong View Profile
Reuters
3 hours ago
- Reuters
European shares end flat as healthcare stocks weigh after Trump's tariff threat
Aug 6 (Reuters) - European shares closed flat on Wednesday, surrendering early session gains, as healthcare stocks felt the pinch from U.S. President Donald Trump's latest threat to impose higher tariffs on pharmaceutical imports. The pan-European STOXX 600 (.STOXX), opens new tab index closed 0.06% lower, breaking its two-day winning streak despite starting the session on a positive note. Healthcare stocks bore the brunt of the selling pressure. The sector index (.SXDP), opens new tab plunged 2.8% to its lowest level in more than three months after Trump unveiled a graduated tariff plan targeting pharmaceutical imports that could see levies on the sector jump up to 250% within 18 months. "This is where it's important to be specific about tariffs because certain stocks and sectors will be impacted differently across regions," said Steve Sosnick, chief market analyst at Interactive Brokers. "In Europe and Asia, investors are considering tariff impacts more carefully since exporters bear much of the brunt directly." The sector was also singed as Novo Nordisk ( opens new tab warned it expects continued competition from copycat versions of its Wegovy obesity drug this year, a message that sent shares of the Danish drug maker down 5.4%. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since then. Meanwhile, Swiss President Karin Keller-Sutter met with U.S. Secretary of State Marco Rubio to discuss potential trade solutions after Trump announced a 39% tariff on Swiss goods. The talks focused on increasing Swiss purchases of U.S. energy and defence products to avert the steep tariff, which threatens significant damage to Switzerland's export-driven economy. Switzerland's benchmark SMI index (.SSMI), opens new tab fell 0.9%, weighed down by drugmakers Novartis (NOVN.S), opens new tab and Roche (ROG.S), opens new tab which lost 3.3% and 2.6%, respectively. Bayer ( opens new tab shares tumbled 9.9% on investor concerns that the German pharmaceutical firm's earnings were inflated by soccer player transfer fees rather than supported by its core healthcare and agriculture businesses. On the data front, Euro zone retail sales grew quicker than thought in June, reinforcing views that the 27-nation bloc remains resilient to trade uncertainty. Among others, Beiersdorf ( opens new tab fell 8.4% and was among top decliners after the German consumer goods maker cut its annual organic sales growth outlook. On the flip side, Siemens Energy ( opens new tab rose 1% after the company said it expects to hit the upper end of its 2025 growth outlook estimates. Hiscox (HSX.L), opens new tab was the top gainer on the index, gaining 9.4% after reporting a rise in first-half insurance premiums supported by its retail business growth.
Reuters
3 hours ago
- Reuters
Charles River profit forecast clouded by order cancellations from biotechs
Aug 6 (Reuters) - Charles River Laboratories' (CRL.N), opens new tab annual profit forecast raise on Wednesday was clouded by investor concerns about the higher number of order cancellations from clients, sending the contract research firm's shares down 8% in afternoon trading. The company's quarterly book-to-bill ratio – the number of orders versus those fulfilled – came in at 0.82x. Evercore ISI analyst Elizabeth Anderson said the ratio was below Wall Street expectations of 0.94x, adding some questions remain about demand environment in the sector. Charles River CEO Jim Foster said on a conference call that while proposals were higher in the quarter, cancellations from biotechs were also higher. Contract research organizations – including Charles River, Fortrea (FTRE.O), opens new tab and ICON (ICLR.O), opens new tab – have posted better-than-expected quarterly profit, reflecting a rebound in spending from pharmaceutical and biotech clients after a cautious stretch driven by tighter sector financing. Charles River's Foster, however, said that funding for smaller biotechs is still more cash constrained, due to the funding slowdown, and mid-sized biotechs are performing better, as many can support their R&D programs without external funding. "We are continuing to see clear signs that the biopharmaceutical demand is stabilizing, and in this environment, we are making gradual progress to return to organic revenue growth," he added. The Wilmington, Massachusetts-based company raised its 2025 adjusted profit forecast to $9.90 to $10.30 per share, from its previous range of $9.30 to $9.80. Charles River's overall second-quarter revenue came in at $1.03 billion, surpassing analysts' estimate of $985.1 million, according to data compiled by LSEG. On an adjusted basis, quarterly profit was $3.12 per share, above estimates of $2.50.
